Latest Sofinnova Stories
Former InterMune CEO Brings Deep Biotech Expertise and Operational Leadership to High Performing Team MENLO PARK, Calif., Jan.
Proceeds Will Be Used to Advance Clinical Programs in Growth Hormone Deficiency and Pulmonary Arterial Hypertension COPENHAGEN, Denmark, Dec.
Genetic Rx Boston Boston, MA (PRWEB) November
New Fund to Invest in Healthcare Products, Diagnostics, Devices, Consumer/OTC Health and Healthcare IT MENLO PARK, Calif., Aug.
SVP IX fund to invest primarily in late-stage biopharmaceutical companies MENLO PARK, Calif., July 23, 2014 /PRNewswire/ -- Sofinnova Ventures, a Menlo Park based investment firm, today
MADRID, July 16, 2014 /PRNewswire/ -- Biospain 2014 is currently seeking and selecting projects for presentation as part of its Investment Forum, one of the most high profile
SUNNYVALE, Calif., June 18, 2014 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced the appointment
Company will draw on leaders' expertise in rare diseases, R&D and commercialization as it moves to complete development of its lead program in inherited blindness PHILADELPHIA, June
Gene therapy leader to advance its deep pipeline of rare disease programs including its lead Phase 3 product candidate for RPE65-related blindness PHILADELPHIA, May 27, 2014 /PRNewswire/
REDWOOD CITY, Calif., May 19, 2014 /PRNewswire/ -- Coherus BioSciences, Inc.
- An imitative word; an onomatopoetic word.